Free shipping on all orders over $ 500

Daclatasvir dihydrochloride

Cat. No. M3693
Daclatasvir dihydrochloride Structure
Synonym:

BMS790052 dihydrochloride

Size Price Availability Quantity
5mg USD 44  USD44 In stock
10mg USD 52  USD52 In stock
50mg USD 65  USD65 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (1-6) activity in vitro. Daclatasvir inhibits the HCV nonstructural protein NS5A.Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Daclatasvir plus asunaprevir provided high sustained virological response rates in treatment-naive, non-responder, and ineligible, intolerant, or ineligible and intolerant patients, and was well tolerated in patients with HCV genotype 1b infection.

Chemical Information
Molecular Weight 811.80
Formula C40H52Cl2N8O6
CAS Number 1009119-65-6
Solubility (25°C) DMSO 148 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Garimella T, et al. J Int AIDS Soc. Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone.

[2] Nettles JH, et al. J Med Chem. Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition.

[3] Dore GJ, et al. Gastroenterology. Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection.

[4] Manns M, et al. Lancet. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Related HCV Protease Products
Hepatitis C Virus S5A/5B

Hepatitis C Virus S5A/5B is a synthetic peptide substrate.

Ac-D-DGla-LI-Cha-C

Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide.

Ac-EEVVAC-pNA

Ac-EEVVAC-pNA is a chromogenic substrate for a continuous spectrophotometric assay of HCV NS3 protease.

Hepatitis Virus C NS3 Protease Inhibitor 2

Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM.

Mipomersen

Mipomersen is a 20-base gapmer (antisense oligonucleotide) that inhibits apolipoprotein B (apoB) and lowers LDL, which can be used in studies related to hyperlipidemia. In addition, Mipomersen has anti-HCV activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Daclatasvir dihydrochloride, BMS790052 dihydrochloride supplier, HCV Protease, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.